Prasco Labs has signed a deal with WellSpring Pharmaceutical Corp. to market an authorized generic version of a drug for a rare tumor disorder.
The Food and Drug Administration has approved a new drug to treat a rare but serious endocrine disorder.
A Food and Drug Administration expert panel has voted unanimously in favor of approval for a Novartis drug for a rare endocrine disorder.